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Objective. Uterine cancer is a major cancer of women, with outcomes potentially worsening with delayed
diagnosis or hysterectomy, the main treatment. Yet cancer surgery wait times are not reported by cancer site.
This study sought to examine changes in wait times for uterine cancer surgery between 2000 and 2009 and to
identify predictors of longer surgery wait times.
Methods. Population-based retrospective analysis of a cohort of uterine cancer patients diagnosed between
April 2000 and March 2009. Using linked administrative data, all cases in which a patient had hysterectomy
following diagnosis were identiﬁed. Wait time was deﬁned as days from diagnosis of uterine cancer (day 0)
to hysterectomy. Regression analysis was used to examine the relationship between covariates and wait time.
Results. Wait times increased steadily between 2000 and 2006 from a median of 34 to 54 days, followed
by a plateau until 2009—during which patients waited a median of between 53 and 55 days for surgery after
diagnosis. Overall, 55% of patients had a wait time longer than 6 weeks after diagnosis. Predictors of a wait
time greater than 6 weeks included older age, region, lower income, later year of diagnosis, surgery by a
gynaecologic oncologist, non-sarcoma histology group and having surgery in a teaching hospital.
Conclusion. Over half of uterine cancer patients waited longer than the recommended 6 weeks for surgery.
Future reporting of cancer wait times by each disease site regularly would help to identify progress to reduce
wait times and opportunities for improvement.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The length of time a patient must wait for the care they need, or
wait times, including for cancer surgery, are an important healthcare
access issue for many countries [1–3]. Long wait times can mean
poorer outcomes, quality of life and quality of care [4,5]. Extensive
waits for treatment can also exact a psychological toll on patients
and families, such as anxiety and distress [6–8]. Prior research haster University, 699 Concession
a. Fax: +1 905 575 6308.
nc. Open access under CC BY-NC-ND licenseindicated that wait times were markedly longer in Canada than
those in other developed countries across a variety of diseases
[9–11]. In a report comparing 14 countries, Canada ranked among
the worst performers in all aspects of access to care [12]. For example,
Canada had the highest proportion of patients (25%) having to wait
4 months or more for elective surgeries, whereas Germany and the
Netherlands had the lowest proportion of 0% and 5%, respectively.
Moreover, within Canada, the province of Ontario's cancer wait
times were among the poorest in the country with only 60%–69% of
patients treated within established benchmarks, whereas the prov-
ince of British Columbia reported proportions of 80%–100% [13].
In 2005, Ontario's Ministry of Health implemented a Wait Time
Strategy to improve quality of care by increasing access and reducing
wait times across several diseases [14]. The Wait Time Strategy
involved an inﬂux of ﬁnancial resources distributed to hospitals on.
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fund was targeted for cancer surgery wait times, as well as cataract
surgery, hip and knee replacement and cardiac procedures [15,16].
Ontario initially invested $10 million to increase surgical volume
across 27 hospitals in 2004–2005 from the baseline cases reported
in 2002–2003. In 2005–2006, they provided a second inﬂux of $27
million to increase cancer surgeries across 37 hospitals by 4,800
cases above the 2002–2003 baseline surgeries [17]. Ontario's cancer
agency, Cancer Care Ontario, was responsible for the implementation
of the cancer Wait Time Strategy speciﬁcally, which aimed to achieve
a 6-week benchmark from diagnosis to surgery for all cancers [14].
Since the implementation of the strategy, Cancer Care Ontario has re-
ported improvements in the wait times of cancer surgeries [18,19].
However, further investigation has shown wide variations by cancer
site. For example, in 2004, median wait time was calculated as
29 days for mastectomy versus the 43 days for hysterectomy [20].
Yet besides this report, limited information is available that is cancer
site speciﬁc, especially beyond the major four cancers (i.e. lung,
breast, colorectal and prostate).
Uterine cancer is the fourth most common cancer and the eighth
most common cause of cancer death for women [21]. The main treat-
ment for uterine cancer is hysterectomy. Of note, the 5-year survival
rate for a woman diagnosed with an early stage uterine cancer (with-
out spread) is 96%, whereas it falls to 16% if diagnosed after the cancer
has spread more distantly [21]. Having a timely hysterectomy after
uterine cancer diagnosis can potentially reduce the risk of cancer pro-
gression and spread. In Ontario, a report published at the onset of the
Wait Time Strategy documents lengthy wait times for hysterectomies
with 75% of surgeries in Ontario occurring at 11.3 weeks, signiﬁcantly
longer than the proposed recommendation of a wait within 6 weeks
of diagnosis of uterine cancer [14]. Despite the documentation of
problems in access to uterine cancer surgery, there has been no
examination of wait times speciﬁc to uterine cancer surgery after
2000 either in Canada or internationally [22].
This study aims to examine thewait times from diagnosis to hyster-
ectomy for uterine cancer from 2000 to 2009 in Ontario, Canada, where
universal health coverage is well established. Our study period includes
the period that the Wait Time Strategy was implemented. Thus, our re-
sults may help to determine the efﬁcacy of the strategy, which can in-
form other jurisdictions that have implemented or are planning to
implement similar strategies. We also investigate predictors of longer
wait times, which can inform future cancer wait times policy.
2. Methods
2.1. Cohort selection
This study included all conﬁrmed uterine cancer patients with a
histopathological diagnosis of ICD-09 codes 179 or 182 in the Ontario
Cancer Registry between April 2000 and March 2009. Patients must
have had a hysterectomy after date of diagnosis (to ensure cancer
diagnosis preceded surgery) and an accompanying Ontario Health
Insurance Plan record. Cases with surgery wait times longer than
730 days were excluded from analysis since the extended wait time
was hypothesized to be due to an extenuating or acute clinical reason.
2.2. Data sources
Data were extracted from various administrative data sets and
linked for analysis. Patient diagnosis year, ICD-09 diagnosis code, con-
ﬁrmation type and date were taken from the Ontario Cancer Registry.
All relevant data pertaining to surgery including date, surgeon speci-
ality and hospital type were derived from the Canadian Institute for
Health Information-Discharge Abstract Database, from 2000 to the
end of March 2011. Ontario Health Insurance Plan records were
used to conﬁrm surgery date and surgeon specialty. Demographicsincluding age, income, rurality and region were gathered from the
Registered Persons Database, the provincial vital statistics registry
and the Statistics Canada 2006 census data. Region was deﬁned
according to Local Health Integration Network Regions. Since 2007,
Ontario is divided into 14 health LHINs or health regions based on
hospital referral patterns and hospital service areas. The LHIN region
of patients was received as dummy codes to prevent patient identiﬁ-
cation. Rurality was deﬁned, using postal code boundaries, as living in
a community whose size was b10, 000 people, as per the census data.
Income was reported as categorical data grouped into ﬁve quintiles.
Diagnosis date was reported by year and age in categories to protect
patient privacy.
2.3. Main outcomes
The primary outcome was wait time, deﬁned as the number of
days between the date of uterine cancer diagnosis by histology
(day 0) and hysterectomy date. The primary analysis was to investi-
gate the change in wait time by year, using calendar year of diagnosis
as a reference date. Secondarily, the effect of covariates on wait times
longer than 6 weeks was examined. Our method of measuring uter-
ine cancer wait times differs slightly from other reported analysis of
wait times. The provincial cancer agency typically deﬁnes surgery
wait time as decision to treat to surgical intervention. Unfortunately,
this can exclude a number of different factors before decision to treat
that can add to the “real” wait time experienced by the patient,
including waiting for the specialist appointments, further radiologic
investigations and time to decision to treat. These factors add days
or weeks to the “real” wait time: one report stated that 40% of pa-
tients with high-risk diagnoses, including cancer and cardiac condi-
tions, waited more than a month to see a specialist [23]. To account
for this added “real time,” Cancer Care Ontario adjusted the 4-week
guideline originally outlined by the Ministry of Health to 6 weeks
for all cancer surgery. For that reason, we used the Cancer Care
Ontario's wait time of 6 weeks as a target wait in our current analysis
[14].
2.4. Statistical analysis
Descriptive statistics were used to summarize patients, and the
following covariates were examined as potential predictors of wait
time: age, rurality, region, year of diagnosis, income, comorbidity,
surgeon type, number of prior cancer diagnosis and surgery location.
Rurality was deﬁned using Statistics Canada 2006 census metropoli-
tan areas and census agglomeration data. Comorbidities were scored
using the Charlson comorbidity index [24]. Logistic regression analy-
sis was used to examine each covariate as a univariable predictor of
wait time greater than 6 weeks. Year squared was deﬁned as a poly-
nomial of degree 2, which allowed for investigation of the ﬁt of year
as a second-order approximation. As a test for sensitivity, a linear
regression analysis was also performed, with wait time deﬁned as a
continuous outcome (with a logarithmic transformation applied for
statistical normalization purposes). Results were similar, so only the lo-
gistic analysis results are reported for brevity. A statistically signiﬁcant
relationship was deﬁned as a p b 0.05. The signiﬁcance of wait time
over time was analysed using one-way ANOVA with a Tukey's post hoc
analysis of signiﬁcance. A multivariable model was constructed using
forward conditional selection method. All analyses were performed
using SPSS (v20) [25].
3. Results
In total, 14,225 patients were identiﬁed in the Ontario Cancer
Registry as having a diagnosis of uterine cancer (ICD-09:179, 182) be-
tween April 1, 2000, and March 31, 2009. After applying the exclusion
criteria, the ﬁnal analysis cohort was 9,330 uterine cancer patients in
Table 1
Demographics of the cohort.
Characteristic N (%)
Age category
18–39 170 (1.8)
40–44 228 (2.4)
45–49 473 (5.1)
50–54 1058 (11.3)
55–59 1666 (17.9)
60–64 1510 (16.2)
65–69 1335 (14.3)
70–74 1133 (12.1)
75–79 890 (9.5)
80+ 867 (9.3)
Year of diagnosis
2000a 636 (6.8)
2001 888 (9.5)
2002 920 (9.9)
153E. O'Leary et al. / Gynecologic Oncology 131 (2013) 151–157Ontario (Fig. 1). A third (30.9%) of cases were over 70 years old, and
933 cases were diagnosed per year on average. The majority of
patients resided in urban centres (86.4%). Half of the cases (53%)
had surgery performed by a gynaecologist compared to 40% who
had surgery by a gynaecologic oncologist. Half of all hysterectomies
in our cohort (47%) were performed in a teaching hospital (Table 1).
Between 2000 and 2006, the overall median wait time increased
by 21 days, with the average number of days wait in a year increasing
between 0.7 and 7.2 days per year. Our analysis shows a statistically
signiﬁcant (p b 0.001) increase in median wait times from 2000
(34 days, range: 1–572) to 2006 (55 days, range: 1–675). The median
wait times of patients diagnosed from 2006 onward levelled off
(Fig. 2), with median wait times of 53 to 55 days. Nearly half of all
patients received surgery in less than 6 weeks after diagnosis
(Fig. 3), which is less than the target of 90%. Of note, 2.6% of patients
had wait times of longer than 6 months.Fig. 1. Consort diagram.
2003 938 (10.1)
2004 1025 (11.0)
2005 988 (10.6)
2006 1150 (12.3)
2007 1195 (12.8)
2008 1271 (13.6)
2009b 319 (3.4)
Patients with a previous cancer diagnosis 763 (8.2)
Two cancers (including uterine) 726 (7.8)
Three cancers (including uterine) 36 (0.4)
Four cancers (including uterine) 1 (0)
Histology
Clear cell 110 (1.2)
Serous 656 (7.0)
Endometrioid 6509 (69.8)
Adenosquamous 645 (6.9)
Sarcoma 696 (7.5)
Adeno unclassiﬁed 714(7.7)
Surgery performed in a teaching hospital 4352 (46.6)
Income
Low 1657 (17.8)
2 1859 (19.9)
3 1851 (19.8)
4 1949 (20.9)
High 1970 (21.1)
Unknown 44 (0.5)
Comorbidity score
0–2 7109 (76.2)
3–12 2221 (23.8)
Specialty of surgeon who performed hysterectomy
Gynaecologic oncologist 3697 (40)
Gynaecologist 4982 (53)
General 122 (1)
Unknown 529 (6)
Rurality
Urban 8060 (86.4)
Rural 1258 (13.5)
Unknown 12 (0.1)
a Data collection was organized in ﬁscal year resulting in only patients diagnosed
from April 1, 2000, to December 31, 2000, included in this category.
b Data collection was organized in ﬁscal year resulting in only patients diagnosed
from January 1, 2009, to March 31, 2009, included in this category.Univariable analysis revealed that older age category, region, later
year of diagnosis, surgeon type, comorbidity index of greater than 2,
histology group and having surgery in a teaching hospital were all
statistically signiﬁcant predictors of increased odds of having a wait
time greater than 6 weeks (Table 2). Given the implementation of
the Wait Time Strategy in 2005 and the observed plateau in wait
times, year of diagnosis was examined pre- and post-2006 and as an
interaction term between ordinal year and diagnosis post-2006
(year squared), which were signiﬁcant in univariate analysis.
Signiﬁcant covariates in the multivariable model included location
of surgery, age category, income quintile, year of diagnosis, histology
and region. The odds of waiting longer than 6 weeks for hysterectomy
Fig. 2. Median wait time by year of diagnosis.
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ing hospital and by 1.04 (95% CI: 1.02–1.07) times for each older age
category of the patient. Conversely, the odds of waiting longer than
6 weeks decreased by 0.96 (95% CI: 0.93–0.99) times for each increase
in income quintile and by 0.45 (95% CI: 0.36–0.58) times if the patient
had a sarcoma histology. Region was signiﬁcantly associated with
longer wait times, some regions positively and others negatively, but
we could not identify the regions due to patient privacy protection.
Year remained statistically signiﬁcant (p b 0.001) even after adjusting
for all other factors.
Additionally, surgeon type was a major factor associated with wait
times in the multivariate model. The odds of waiting longer than
6 weeks for hysterectomy was increased by 3.20 times (95% conﬁ-
dence interval [CI]: 2.59 to 5.93) if the surgery was performed by a
gynaecologic oncologist. Moreover, from 2000 to 2009, we noted
that there was an increase in surgeries performed by gynaecologic
oncologists while surgeries performed by gynaecologic surgeons
decreased. Gynaecologic oncologists saw an increase of surgeries
from 29% of hysterectomies in 2000 to 52% in 2009 (40% overall),
whereas gynaecologic surgeons performed 64% of surgeries in 2000
to 44% in 2009.Fig. 3. Percent of cases by wait time categories.4. Discussion
In this study of wait times for uterine cancer surgery in Ontario,
Canada, median wait time steadily increased by an average of
3 days/year between 2000 and 2006 and then plateaued between
2007 and 2009 at approximately 53–55 days. At the plateau, less
than half of patients were treated with surgery within the 6-week
target. Despite knowledge that cancer surgery wait times vary greatly
by disease site [20]. Wait times have not typically been reported by
site but rather as an aggregate wait time for all cancer surgeries.
Only one study by Kwon et al. [22] previously examined uterine can-
cer wait times between 1996 and 2000 in Ontario. To our knowledge,
this is the ﬁrst study speciﬁcally to examine uterine cancer surgery
wait times since 2000 in Ontario or internationally.
In both Kwon et al. [22] and this current analysis, a signiﬁcant re-
lationship is identiﬁed between surgeon type and wait time; howev-
er, there are two major differences in our study results. First, our data
show there was an increase in the frequency for which patients with
uterine cancer were referred to gynaecologic oncologists for treat-
ment. Between 1996 and 2000, only 19.5% of endometrial cancer
cases were performed by gynaecologic oncologists, but in the present
analysis, 40% were referred between 2000 and 2009. The increased
referral rate to oncologist specialists since 2000 likely results from a
practice change where some women with high-risk histologies, or
complex cases who were previously treated by gynaecologists were
now increasingly being referred to specialized expertise from a
gynaecologic oncologist and/or perioperative care in a teaching hos-
pital [26–28]. However, our data also show that only a small number
of referrals to specialists were for high-risk histologies: of surgeries
performed by gynaecologic oncologists, only 24% were for cases with
high-risk histologies, including clear cell, serous or sarcoma, compared
with 11% for surgeries performed by non-gynaecologic oncologists.
Thus, although referrals to a specialist implies adherence to guideline
recommendations, more education about appropriate referrals can
support more timely patient care.
Second, themedianwait for a surgerywith a gynaecologic-oncologist
surgeon was longer in our analysis (63 days) compared to Kwon's
analysis prior to 2000 (41 days). As well, the median wait time only
increased gradually from 1996 to 2000 (28 to 33 days), whereas a
much greater prolongation of wait times was observed from 2000 to
2006. This occurred partially as a result of the increase in the incidence
of uterine cancers by 0.7% annually between 1997 and 2007 [29]. As
well, during our study period, the number of gynaecologic oncologists
only increased from 26 to 29, while the number of surgeries performed
by gynaecologic oncologists increased 23%. Therefore, having more
providers trained to perform uterine cancer surgery could help to reduce
wait times.
Additionally, the median wait time plateaued after 2006. This pla-
teau coincides with the implementation of the Wait Time Strategy.
The Wait Time Strategy for cancer surgery areas speciﬁcally used a
single approach, which was to provide more healthcare dollars for
each surgical case as it was performed, given to the facility (not the
providers) for use without stipulations [30]. It is possible that the
renewed ﬁnancial resources for each surgery may have contributed
to the plateau by supporting an increase in surgeries per hospital;
however, the additional dollars per surgery did not translate into a
wait time less than 6 weeks, as per the CCOs benchmark for cancer
surgery. Furthermore, the Canadian Institute for Health Information
reported in 2007 that wait time data available were more accurate
and accessible than had been in the past, and thus the levelling off
in wait times post-2006 may also be due to more accurate data
reporting [31].
Another plausible contributing explanation for the wait time
plateau includes the fact that post-2006, the surgical approach for
uterine cancer changed from laparotomy to laparoscopy, which is
known to be a statistically longer procedure [32–35]. One might
Table 2
Logistic regression analysis of wait times greater than 6 weeks.
Factor Group Odds ratio (95% CI) p-value
Univariate analysis
Age category 1.032 (1.013–1.052) 0.001
Regiond b0.001
LHIN A 0.984 (0.752–1.287) 0.907
LHIN C 3.125 (2.472–3.950) b0.001
LHIN D 0.753 (0.518–1.093) 0.136
LHIN E 0.831 (0.631–1.095) 0.188
LHIN F 0.741 (0.577–0.952) 0.019
LHIN G 1.927 (1.543–2.408) b0.001
LHIN H 1.358 (1.085–1.701) 0.008
LHIN I 1.518 (1.212–1.900) b0.001
LHIN J 0.838 (0.654–1.072) 0.159
LHIN K 1.106 (0.897–1.364) 0.344
LHIN L 0.957 (0.779–1.177) 0.679
LHIN M 1.164 (0.944–1.436) 0.155
LHIN N 1.565 (1.203–2.037) 0.001
Increasing income quintile 0.989 (0.961–1.018) 0.456
Year of diagnosis 1.168 (1.150–1.187) b0.001
Surgeon typea b0.001
Gynaecologic Oncologist 7.074 (5.236–11.335)
Gynaecologic surgeon 1.214 (0.828–1.779)
No surgeon listed 3.319 (2.188–5.034)
Histology groupb b0.001
Clear cell 1.142 (0.762–1.711)
Serous 1.464 (1.180–1.816)
Endometrioid 1.040 (0.890–1.214)
Adenosquamous 1.684 (1.353–2.097)
Sarcoma 0.889 (0.721–1.096)
Surgery in a teaching hospital 4.651 (4.255–5.076) b0.001
Diagnosis post-2006 1.836 (1.675–2.013) b0.001
Year squared interaction 0.967 (0.961–0.972) b0.001
Comorbidity greater than two 1.517 (5.236–11.335) b0.001
Ruralityc 0.076
Urban 1.138 (1.010–1.281)
Multivariate analysise
Age category 1.042 (1.020–1.065) b0.001
Regiond b0.001
LHIN A 1.163 (0.862–1.569) 0.323
LHIN C 1.294 (0.990–1.690) 0.059
LHIN D 1.169 (0.778–1.754) 0.452
LHIN E 0.651 (0.477–0.888) 0.007
LHIN F 0.919 (0.695–1.214) 0.551
LHIN G 1.483 (1.153–1.907) 0.002
LHIN H 1.027 (0.789–1.323) 0.834
LHIN I 1.508 (1.172–1.939) 0.001
LHIN J 0.945 (0.717–1.246) 0.688
LHIN K 1.190 (0.941–1.505) 0.146
LHIN L 0.761 (0.602–0.961) 0.022
LHIN M 1.092 (0.862–1.382) 0.466
LHIN N 1.509 (1.125–2.025) 0.006
Increasing income quintile 0.960 (0.928–0.992) 0.016
Year of diagnosis 1.148 (1.128–1.169) b0.001
Surgeon typea b0.001
Gynaecologic oncologist 3.197 (2.590–5.926)
Gynaecologic surgeon 0.985 (0.662–1.466)
No surgeon listed 2.163 (1.396–3.351)
Histology groupb b0.001
Clear Cell 0.725 (.0459–1.145)
Serous 0.812 (0.633–1.014)
Endometrioid 1.004 (0.840–1.200)
Adenosquamous 1.277 (0.993–1.642)
Sarcoma 0.453 (0.356–0.577)
Surgery in a teaching hospital 1.916 (1.675–2.192) b0.001
Note: 44 of the original 9330 cases had invalid/missing regional data and could not be included in analysis.
a General surgeon is the constant for surgeon type.
b Adeno unclassiﬁed is the constant for histology.
c Rural is the constant for rurality
d The 14 regions are blinded and therefore we cannot attribute results to a speciﬁc region
e In the multivariate analysis, 4 variables were not signiﬁcant after applying the forward conditional selection method and not included.
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oncologists were learning this new procedure which, along with the
lengthier procedure, resulted in increased needs for operating roomresources and time. Indeed our data show that there was an increased
odds of a wait greater than 6 weeks if the surgery was performed by a
gynaecologic oncologist or if in a teaching facility (Table 2).
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through our decade-long study period, our results may partially
reﬂect the effectiveness of the strategy. Finding no other studies to
compare uterine cancer wait times, our results could imply effective-
ness since the wait times in uterine cancer plateaued and did not
further increase; however, they could also imply ineffectiveness
since the wait times did not ultimately decrease. In contrast, wait
times decreased in breast cancer surgery in the province during that
period, where 90% of patients had surgery in 45 days in 2005 and
that was reduced to 35 days in 2008 [36]. A cross-national compari-
son of surgical wait times strategies in ﬁve countries concluded that
strategies were “less successful” in Canada, whereas England has
had the “most pronounced success in reducing excessive wait
times.” [37] The Ontario Strategy entailed targeted ﬁnancial resources
to hospitals performing cancer surgeries and establishment of target
benchmarks. England also set targets and provided large funding
boosts, but in addition, they introduced a robust performance
management system, where hospitals' performance were managed
by independent inspection and a public performance rating system.
The English government also bought additional private-sector capac-
ity to perform elective treatments to further reduce wait times.
Perhaps, uterine cancer wait times could be further decreased by
introducing additional strategies such as those employed by England
[37].
Our study has limitations. Increased cancer grade has been linked
to longer wait time in endometrial cancer, yet grade or stage data
were not available to be included in our analysis [22]. We could not
determine reasons for longer wait times, and reasons such as patient
preferences or other clinical considerations (adjuvant therapy or
extensive comorbidities for example) may be contributing factors.
Conversely, we could not determine whether the strategy was
primarily responsible for the plateau in wait times post-2006 since
this was not the primary aim of the study. This is the ﬁrst study to
examine uterine cancer wait times since 2000 in a healthcare system
with universal access and thus may act as a useful comparison; how-
ever, wait times in other jurisdictions and countries may differ. None-
theless, the policies and practice pattern trends that could explain the
changing wait times could be applicable to other countries. Further
research should examine wait times in other jurisdictions and the
effect of longer wait times on patient outcomes, such as survival.
Following the inﬂux of ﬁnancial resources to hospitals for cancer
surgery post-2006, there has been a plateau in wait times for uterine
cancer, in contrast to the decrease in wait times in other cancer sites
[20]. Increasing surgeries by specialists, little growth in the numbers
of practicing gynaecologic oncologists, the introduction of a laparo-
scopic approach and the use of a single approach Wait Time Strategy
may have contributed to the rise and eventual plateau in wait times
speciﬁcally for uterine cancer. Nonetheless, with just under half of
patients receiving surgery within the target guideline of 6 weeks,
wait times still need improvement. Our analysis suggests that it is
useful to examine cancer surgery wait times by disease site regularly,
so as to illuminate site-speciﬁc recommendations that can help to
improve cancer care for a particular disease site group.Conﬂict of interest statement
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